Apitegromab (Isembyld) for Spinal muscular atrophy (SMA)
What the FDA decided
The FDA approved Scholar Rock's BLA for Apitegromab (Isembyld) in Spinal muscular atrophy (SMA). Approved 19 days ahead of its September 30th action date as the first muscle-targeted treatment for SMA. The label requires patients to already be on an SMN2-targeted therapy, making it an add-on rather than a replacement.
Who this decision matters to
Spinal muscular atrophy is an autosomal recessive genetic disorder affecting motor neurons in the spinal cord, causing progressive muscle weakness and atrophy. The condition results from deficiency of SMN (survival motor neuron) protein. Gene therapy and antisense drugs have transformed SMA outcomes since 2016, and a first muscle-targeted add-on was approved in 2026.
Prevalence: 1 in 10,000 to 14,000 births; 1 in 25 people are carriers. See our full Spinal Muscular Atrophy page for current treatments, recruiting trials, and community resources.
Where Spinal Muscular Atrophy treatment stands today
Read our full Spinal Muscular Atrophy treatment summary
SMA now has two separate kinds of treatment, and the distinction matters when you are weighing trials. SMN-targeted therapies protect motor neurons and include Spinraza, Evrysdi, the one-time gene therapy Zolgensma, given by IV infusion to children under 2, and Itvisma (onasemnogene abeparvovec-brve), a one-time gene therapy injected into the spinal fluid (intrathecal) that the FDA approved in November 2025 for patients 2 years and older.
Muscle-targeted therapy is newer: apitegromab (Isembyld) was approved in September 2026 as an add-on for patients 2 and older who are already on Spinraza or Evrysdi, making it the first drug aimed at the muscle rather than the nerve. Research continues on improved delivery, new splicing approaches, and further muscle-directed agents.
Early diagnosis through newborn screening, where available, is critical for outcomes, and Cure SMA and patient registries help families compare options. Your pediatric or adult neuromuscular specialist can discuss which approved therapies and which open trials match your SMA type and current function.
Ask your team to record a baseline motor function score before starting anything new, since that number is what any later decision to continue or stop will be measured against.
The Spinal Muscular Atrophy page has every treatment and trial →Meanwhile, 62 Spinal Muscular Atrophy trials are recruiting
Whatever the FDA decides here, research on Spinal Muscular Atrophy does not stop. A few currently enrolling studies, US sites first:
You'll hear about future FDA decisions and new recruiting trials for Spinal Muscular Atrophy. Unsubscribe anytime.
Frequently asked questions
Has the FDA decided on Apitegromab?
The FDA has already decided. It approved the application.
Details: the outcome and what it means are at the top of this page.
Source: Scholar Rock press release
What was Apitegromab approved for?
The FDA approved Scholar Rock's BLA for Apitegromab in Spinal muscular atrophy (SMA).
What to know: Approved 19 days ahead of its September 30th action date as the first muscle-targeted treatment for SMA. The label requires patients to already be on an SMN2-targeted therapy, making it an add-on rather than a replacement.
Is there already an FDA-approved treatment for Spinal Muscular Atrophy?
Yes. Trial Friend's drug list includes 5 FDA-approved drugs for Spinal Muscular Atrophy.
Approved: Spinraza (nusinersen), Zolgensma (onasemnogene abeparvovec), Evrysdi (risdiplam), Itvisma (onasemnogene abeparvovec-brve), Isembyld (apitegromab).
Check: the Spinal Muscular Atrophy page also searches FDA drug labels for approved treatments.
How much will Apitegromab cost?
Trial Friend does not list a price for Apitegromab. What you pay depends on your insurance and on help from the drugmaker or a charity fund.
Help paying: drugmaker programs and charity funds usually open at launch.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Apitegromab decision?
This page updates with the outcome the day it is announced.
If approved: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.
If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Scholar Rock press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.